MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Humphreys, C. J.
Right arrow Articles by Rudnick, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Humphreys, C. J.
Right arrow Articles by Rudnick, G.

Antidepressant binding to the porcine and human platelet serotonin transporters

CJ Humphreys, J Levin and G Rudnick

Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06510.

The ability of four antidepressant drugs, imipramine, alaproclate, norzimelidine, and fluvoxamine, to inhibit serotonin transport into platelet plasma membrane vesicles was tested over a range of external Na+ concentrations. Imipramine affinity, as we previously reported [J. Biol. Chem. 258:6115-6119 (1983)] increases sigmoidally with Na+. When measured by inhibition of serotonin transport, the affinity for alaproclate and norzimelidine is much less sensitive to Na+ and fluvoxamine actually inhibits more avidly at lower Na+. All of the drugs competitively inhibit serotonin transport. Moreover, alaproclate, norzimelidine, and fluvoxamine all competitively displace [3H]imipramine from platelet plasma membranes. The Ki for fluvoxamine inhibition of transport is 16-fold higher than its Ki for inhibition of imipramine binding. In contrast, alaproclate inhibits transport at concentrations lower than those required to block imipramine binding. In the case of fluvoxamine, and possibly also alaproclate, these differences are not due to separate sites mediating substrate and imipramine binding but rather to differences in the nature of binding and transport measurements. The results suggest that these antidepressant drugs and serotonin all bind to the same site, or to overlapping sites on the serotonin transporter, or to sites on the transporter whose occupation is mutually exclusive with substrate site occupation. The observation that binding of each ligand reacts differently to changes in Na+ suggests that distinct subsites are involved in each case. As reported previously by Wennogle and Myerson [Eur. J. Pharmacol. 86:303-307 (1983)] serotonin decreases the rate of imipramine dissociation from human platelet membranes. This effect is not observed in porcine platelets, is not Na+ dependent, and requires serotonin concentrations over 100 times the Km for transport. It is likely, therefore, to result from serotonin binding to a site distinct from the transport active site.

Volume 33, Issue 6, pp. 657-663, 06/01/1988
Copyright © 1988 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
Pharmacol. Rev.Home page
G. Pineyro and P. Blier
Autoregulation of Serotonin Neurons: Role in Antidepressant Drug Action
Pharmacol. Rev., September 1, 1999; 51(3): 533 - 591.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
C. Sur, H. Betz, and P. Schloss
A single serine residue controls the cation dependence of substrate transport by the rat serotonin transporter
PNAS, July 8, 1997; 94(14): 7639 - 7644.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1988 by the American Society for Pharmacology and Experimental Therapeutics